Cidara Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -45,000 | -27 | -49 | -90,753 |
EBITDA | -83,205 | -27,357 | -25,220 | -54,123 |
EBIT | -83,233 | -27,384 | -25,269 | -54,182 |
Net Income | -83,233 | -25,718 | -23,480 | -52,307 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -40,615 | -40,961 | -21,950 | -29,414 |
Cash | 293,651 | 510,575 | 168,150 | 189,825 |
Basic Shares | 15,547 | 15,547 | 14,177 | 9,727 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,275 | $23,283 | $64,288 | $49,572 |
Gross Profit | 1,275 | -13,480 | 64,288 | 49,572 |
EBITDA | -175,869 | -26,948 | -28,493 | -43,485 |
EBIT | -176,102 | -27,060 | -29,718 | -42,255 |
Net Income | -169,827 | -22,931 | -29,799 | -43,909 |
Net Change In Cash | 1,275 | 23,283 | 64,288 | 49,572 |
Cost of Revenue | -29,542 | |||
Free Cash Flow | -176,662 | -22,937 | -28,591 | -25,273 |
Cash | 189,825 | 35,778 | 32,731 | 62,273 |
Basic Shares | 6,349 | 4,371 | 3,492 | 2,622 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$3.10 |
2025-06-30 | -$1.65 |
2025-03-31 | -$1.66 |
2024-12-31 | -$5.38 |
